Illicit drugs, alcohol, and addiction in human immunodeficiency virus

Panminerva Medica

Volumn 49, Issue 2, 2007, Pages 67-77

  Samet, J H ^a,b,c   Walley, A Y ^a   Bridden, C ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY   (United States)

^c Medicine and Public Health   (United States)

Author keywords

HIV infections; Risk factors; Substance related disorders

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADDICTION; ALCOHOLISM; DISEASE COURSE; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT COMPLIANCE; PREVALENCE; REVIEW; RISK REDUCTION;

ALCOHOLISM; ANTI-HIV AGENTS; DISEASE PROGRESSION; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; PREVALENCE; RISK REDUCTION BEHAVIOR; RISK-TAKING; SUBSTANCE-RELATED DISORDERS;

EID: 34547735420     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (133)

1. UNAIDS. Report on the global AIDS epidemic 2006. 2006. Available at: http://www.unaids.org/en/HIV_data/2006GlobalReport/default.asp. Accessed June 26, 2007.
2. Aceijas C, Stimson GV, Hickman M, Rhodes T. Global overview of injecting drug use and HIV infection among injecting drug users. AIDS 2004;18:2295-303.
3. UNAIDS. At risk and neglected: four key populations. 2006. Available at: http://data.unaids.org/pub/GlobalReport/2006/2006_GR_CH05_ en.pdf. Accessed June 26, 2007.
4. Dehne KL, Pokrovskiy V, Kobyshcha Y, Schwartlander B. Update on the epidemics of HIV and other sexually transmitted infections in the newly independent states of the former Soviet Union. AIDS 2000;14 Suppl 3:S75-S84.
5. Hamers FF, Downs AM. HIV in central and eastern Europe. Lancet 2003;361:1035-44.
6. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2004. Atlanta, US Department of Health and Human Services, Centers for Disease Control and Prevention. 2005. Available at: http://www.cdc.gov/hiv/topics/ surveillance/resources/reports/2004report/pdf/2004SurveillanceReport.pdf. Accessed June 26, 2007.
7. Centers for Disease Control and Prevention. AIDS Surveillance - General Epidemiology (through 2005). Atlanta, US Department of Health and Human Services, Centers for Disease Control and Prevention. 2007. Available at: http://www.cdc.gov/hiv/topics/surveillance/resources/slides/epidemiology/index. htm. Accessed June 26, 2007.
8. Lefevre F, O'Leary B, Moran M, Mossar M, Yarnold PR, Martin GJ et al. Alcohol consumption among HIV-infected patients. J Gen Intern Med 1995;10:458-60.
9. Conigliaro J, Gordon AJ, McGinnis KA, Rabeneck L, Justice AC. How harmful is hazardous alcohol use and abuse in HIV infection: do health care providers know who is at risk? J Acquir Immune Defic Syndr 2003;33:521-5.
10. Krupitsky EM, Horton NJ, Williams EC, Lioznov D, Kuznetsova M, Zvartau E et al. Alcohol use and HIV risk behaviors among HIV-infected hospitalized patients in St. Petersburg, Russia. Drug Alcohol Depend 2005;79:251-6.
11. Mbulaiteye SM, Ruberantwari A, Nakiyingi JS, Carpenter LM, Kamali A, Whitworth JA. Alcohol and HIV: a study among sexually active adults in rural southwest Uganda. Int J Epidemiol 2000;29:911-5.
12. Drumright LN, Patterson TL, Strathdee SA. Club drugs as causal risk factors for HIV acquisition among men who have sex with men: a review. Subst Use Misuse 2006;41:1551-601.
13. Buchanan D, Tooze JA, Shaw S, Kinzly M, Heimer R, Singer M. Demographic, HIV risk behavior, and health status characteristics of "crack" cocaine injectors compared to other injection drug users in three New England cities. Drug Alcohol Depend 2006;81:221-9.
14. Lorvick J, Martinez A, Gee L, Krai AH. Sexual and injection risk among women who inject methamphetamine in San Francisco. J Urban Health 2006;83:497-505.
15. Molitor F, Ruiz JD, Flynn N, Mikanda JN, Sun RK, Anderson R. Methamphetamine use and sexual and injection risk behaviors among out-of-treatment injection drug users. Am J Drug Alcohol Abuse 1999;25:475-93.
16. Booth RE, Kwiatkowski CF, Chitwood DD. Sex related HIV risk behaviors: differential risks among injection drug users, crack smokers, and injection drug users who smoke crack. Drug Alcohol Depend 2000;58:219-26.
17. Mansergh G, Purcell DW, Stall R, McFarlane M, Semaan S, Valentine J, Valdiserri R. CDC consultation on methamphetamine use and sexual risk behavior for HIV/STD infection: summary and suggestions. Public Health Rep 2006;121:127-32.
18. Plankey MW, Ostrow DG, Stall R, Cox C, Li X, Peck JA et al. The relationship between methamphetamine and popper use and risk of HIV seroconversion in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2007;45:85-92.
19. Centers for Disease Control and Prevention (CDC). Methamphetamine use and HIV risk behaviors among heterosexual men: preliminary results from five northern California counties, December 2001 -November 2003. MMWR Morb Mortal Wkly Rep 2006;55:273-7.
20. Kozlov AP, Shaboltas AV, Toussova OV, Verevochkin SV, Masse BR, Perdue T et al. HIV incidence and factors associated with HIV acquisition among injection drug users in St Petersburg, Russia. AIDS 2006;20:901-6.
21. Pechansky F, Woody G, Inciardi J, Surratt H, Kessler F, Von Diemen L et al. HW seroprevalence among drug users: an analysis of selected variables based on 10 years of data collection in Porto Alegre, Brazil. Drug Alcohol Depend 2006;82 Suppl 1:8109-13.
22. Kalichman SC, Simbayi LC, Vermaak R, Cain D, Jooste S, Peltzer K. HIV/AIDS risk reduction counseling for alcohol using sexually transmitted infections clinic patients in Cape Town, South Africa. J Acquir Immune Defic Syndr 2007;44:594-600.
23. Weiser SD, Leiter K, Heisler M, McFarland W, Percy-de Korte F, DeMonner SM et al. A population-based study on alcohol and high-risk sexual behaviors in Botswana. PLoS Med 2006;3:e392.
24. Simbayi LC, Kalichman SC, Jooste S, Mathiti V, Cain D, Cherry C. Alcohol use and sexual risks for HIV infection among men and women receiving sexually transmitted infection clinic services in Cape Town, South Africa. J Stud Alcohol 2004;65:434-42.
25. Mnyika KS, Klepp KI, Kvale G, Ole-King'ori N. Risk factors for HIV-1 infection among women in the Arusha region of Tanzania. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:484-91.
26. Rees V, Saitz R, Horton NJ, Samet J. Association of alcohol consumption with HIV sex- and drug-risk behaviors among drug users. J Subst Abuse Treat 2001;21:129-34.
27. Stein MD, Hanna L, Natarajan R, Clarke J, Marisi M, Sobota M et al. Alcohol use patterns predict high-risk HIV behaviors among active injection drug users. J Subst Abuse Treat 2000;18:359-63.
28. Walley AY, Krupitsky EM, Cheng DM, Raj A, Edwards EM, Bridden C et al. Implications of cannabis use and heavy alcohol use on HIV drug risk behaviors in Russian heroin users. AIDS Behav 2007; [Epub ahead of print].
29. Beckett M, Burnam A, Collins RL, Kanouse DE, Beckman R. Substance use and high-risk sex among people with HIV: a comparison across exposure groups. AIDS Behav 2003;7:209-19.
30. Morin SF, Myers JJ, Shade SB, Koester K, Maiorana A, Rose CD. Predicting HIV transmission risk among HIV-infected patients seen in clinical settings. AIDS Behav 2007; [Epub ahead of print].
31. Shoptaw S, Reback CJ, Freese TE. Patient characteristics, HIV serostatus, and risk behaviors among gay and bisexual males seeking treatment for methamphetamine abuse and dependence in Los Angeles. J Addict Dis 2002;21:91-105.
32. Ehrenstein V, Horton NJ, Samet JH. Inconsistent condom use among HIV-infected patients with alcohol problems. Drug Alcohol Depend 2004;73:159-66.
33. Cohn JA. HIV-1 infection in injection drug users. Infect Dis Clin North Am 2002;16:745-70.
34. Moore RD, Keruly JC, Chaisson RE. Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. J Acquir Immune Defic Syndr 2004;35:46-51.
35. Keiser O, Taffe P, Zwahlen M, Battegay M, Bernasconi E, Weber R et al.; And the Swiss HIV Cohort Study. All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population. AIDS 2004;18:1835-43.
36. Perez-Hoyos S, del Amo J, Muga R, del Romero J, Garcia de Olalla P, Guerrero R et al.; GEMES (Spanish Multicenter Study Group of Seroconverters). Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category. AIDS 2003;17:353-9.
37. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 2001;15:1115-23.
38. Chander G, Himelhoch S, Moore RD. Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy. Drugs 2006;66:769-89.
39. Marimoutou C, Carrieri P, Poizot-Martin I, Loundou A, Tremolieres F, Rey D et al.; MINIF 2000 Study Group. Hospitalization for depressive syndrome in a cohort of HIV-infected patients contaminated through injecting drug use: MANIF 2000 cohort, France, 1995-1999. AIDS Care 2003;15:729-34.
40. Johnson ME, Yep MJ, Brems C, Theno SA, Fisher DG. Relationship among gender, depression, and needle sharing in a sample of injection drug users. Psychol Addict Behav 2002;16:338-41.
41. Wisniewski AB, Apel S, Seines OA, Nath A, McArthur JC, Dobs AS. Depressive symptoms, quality of life, and neuropsychological performance in HIV/AIDS: the impact of gender and injection drug use. J Neurovirol 2005;11:138-43.
42. Disney E, Kidorf M, Kolodner K, King V, Peirce J, Beilenson P et al. Psychiatric comorbidity is associated with drug use and HIV risk in syringe exchange participants. J Nerv Ment Dis 2006;194:577-83.
43. Ickovics JR, Hamburger ME, Vlahov D, Schoenbaum EE, Schuman P, Boland RJ et al.; HIV Epidemiology Research Study Group. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001;285:1466-74.
44. Lundgren LM, Amodeo M, Chassler D. Mental health status, drug treatment use, and needle sharing among injection drug users. AIDS Educ Prev 2005;17:525-39.
45. Lucas GM, Griswold M, Gebo KA, Keruly J, Chaisson RE, Moore RD. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol 2006;163:412-20.
46. Kapadia F, Cook JA, Cohen MH, Sohler N, Kovacs A, Greenblatt RM et al. The relationship between non-injection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use. Addiction 2005;100:990-1002.
47. Walley A, Cheng DM, Libman H. Recent drug use and homelessness are associated with increased short-term mortality in HIV-infected persons with alcohol problems. J Gen Intern Med 2007;22:158.
48. Celentano DD, Galai N, Sethi AK, Shah NG, Strathdee SA, Vlahov D et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 2001;15:1707-15.
49. Samet JH, Freedberg KA, Stein MD, Lewis R, Savetsky J, Sullivan L et al. Trillion virion delay: time from testing positive for HIV to presentation for primary care. Arch Intern Med 1998;158:734-40.
50. Clarke S, Delamere S, McCullough L, Hopkins S, Bergin C, Mulcahy F. Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting drug users. HIV Med 2003;4:33-7.
51. Hsu LC, Vittinghoff E, Katz MH, Schwarcz SK. Predictors of use of highly active antiretroviral therapy (HAART) among persons with AIDS in San Francisco, 1996-1999. J Acquir Immune Defic Syndr 2001;28:345-50.
52. O'Connor PG, Selwyn PA, Schottenfeld RS. Medical care for injection-drug users with human immunodeficiency virus infection. N Engl J Med 1994;331:450-9.
53. Amsten JH, Demas PA, Grant RW, Gourevitch MN, Farzadegan H, Howard AA et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med 2002;17:377-81.
54. Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr 2006;43:411-7.
55. Golin CE, Liu H, Hays RD, Miller LG, Beck CK, Ickovics J et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med 2002;17:756-65.
56. Howard AA, Arnsten JH, Lo Y, Vlahov D, Rich JD, Schuman P et al.; HER Study Group. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS 2002;16:2175-82.
57. Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002;16:767-74.
58. Moss AR, Hahn JA, Perry S, Charlebois ED, Guzman D, Clark RA et al. Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study. Clin Infect Dis 2004;39:1190-8.
59. Palepu A, Tyndall MW, Li K, Tip B, O'Shaughnessy MV, Schechter MT et al. Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy. J Urban Health 2003;80:667-75.
60. Palepu A, Tyndall M, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. J Acquir Immune Defic Syndr 2003;32:522-6.
61. Samet JH, Horton NJ, Traphagen ET, Lyon SM, Freedberg KA. Alcohol consumption and HIV disease progression: are they related? Alcohol Clin Exp Res 2003;27:862-7.
62. Joe GW, Simpson DD. Mortality rates among opioid addicts in a longitudinal study. Am J Public Health 1987;77:347-8.
63. Wang C, Vlahov D, Galai N, Cole SR, Bareta J, Pollini R et al. The effect of HIV infection on overdose mortality. AIDS 2005;19:935-42.
64. Hwang SW. Mortality among men using homeless shelters in Toronto, Ontario. JAMA 2000;283:2152-7.
65. Rees VW, Horton NJ, Hingson RW, Saitz R, Samet JH. Injury among detoxification patients: alcohol users' greater risk. Alcohol Clin Exp Res 2002;26:212-7.
66. Mientjes GH, Miedema F, van Ameijden EJ, van den Hoek AA, Schellekens PT, Roos MT et al. Frequent injecting impairs lymphocyte reactivity in HIV-positive and HIV-negative drug users. AIDS 1991;5:35-41.
67. Bagby GJ, Zhang P, Purcell JE, Didier PJ, Nelson S. Chronic binge ethanol consumption accelerates progression of simian immunodeficiency virus disease. Alcohol Clin Exp Res 2006;30:1781-90.
68. Pavia CS, La MM, Kavanagh M. Influence of alcohol on antimicrobial immunity. Biomed Pharmacother 2004;58:84-9.
69. Dingle GA, Oei TP. Is alcohol a cofactor of HIV and AIDS? Evidence from immunological and behavioral studies. Psychol Bull 1997;122:56-71.
70. Samet J, Cheng D, Libman H, Nunes D, Alperen J, Saitz R. Alcohol consumption and HIV disease progression. J Acquir Immune Defic Syndr. In press 2007.
71. Ding L, Landon BE, Wilson IB, Wong MD, Shapiro MF, Cleary PD. Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users. Arch Intern Med 2005;165:618-23.
72. Hinkin CH, Barclay TR, Castellon SA, Levine AJ, Durvasula RS, Marion SD et al. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav 2007;11:185-94.
73. Cook RL, Sereika SM, Hunt SC, Woodward WC, Erlen JA, Conigliaro J. Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med 2001;16:83-8.
74. Samet JH, Horton NJ, Meli S, Freedberg KA, Palepu A. Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcohol Clin Exp Res 2004;28:572-7.
75. Berg KM, Demas PA, Howard AA, Schoenbaum EE, Gourevitch MN, Arnsten JH. Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med 2004;19:1111-7.
76. Marco A, Cayla JA, Serra M, Pedro R, Sanrama C, Guerrero R et al. Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release. Study Group of Adherence to Tuberculosis Treatment of Prisoners. Eur Respir J 1998;12:967-71.
77. Altice FL, Mezger JA, Hodges J, Bruce RD, Marinovich A, Walton M, Springer SA, Friedland GH. Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replication. Clin Infect Dis 2004;38 Suppl 5:5376-87.
78. McCance-Katz EF, Gourevitch MN, Arnsten J, Sarlo J, Rainey P, Jatlow P. Modified directly observed therapy (MDOT) for injection drug users with HIV disease. Am J Addict 2002;11:271-8.
79. Sherer R. Adherence and antiretroviral therapy in injection drug users. JAMA 1998;280:567-8.
80. Ware NC, Wyatt MA, Tugenberg T. Adherence, stereotyping and unequal HIV treatment for active users of illegal drugs. Soc Sci Med 2005;61:565-76.
81. Gibson DR, Flynn NM, Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS 2001;15:1329-41.
82. Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse 2006;41:777-813.
83. Fisher DG, Fenaughty AM, Cagle HH, Wells RS. Needle exchange and injection drug use frequency: a randomized clinical trial. J Acquir Immune Defic Syndr 2003;33:199-205.
84. Burak J, Bansberg D. Epidemiology and HIV transmission in injection drug users. HIV InSite; 1998.: http://hivinsite.ucsf.edu/InSite?page= kb-07&doc=kb-07-04-01. Accessed June 26, 2007.
85. Wodak A. Harm reduction: Australia as a case study. Bull N Y Acad Med 1995;72:339-47.
86. Des Jarlais DC, Hagan H, Friedman SR, Friedmann P, Goldberg D, Frischer M et al. Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA 1995;274:1226-31.
87. Kamb ML, Fishbein M, Douglas JM Jr, Rhodes F, Rogers J, Bolan G et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. JAMA 1998;280: 1161-7.
88. Merson MH, Dayton JM, O'Reilly K. Effectiveness of HIV prevention interventions in developing countries. AIDS 2000;14 Suppl 2:S68-S84.
89. Margolin A, Avants SK, Warburton LA, Hawkins KA, Shi J. A randomized clinical trial of a manual-guided risk reduction intervention for HIV-positive injection drug users. Health Psychol 2003;22:223-8.
90. Rotheram-Borus MJ, Lee MB, Murphy DA, Futterman D, Duan N, Birnbaum JM et al.; Teens Linked to Care Consortium. Efficacy of a preventive intervention for youths living with HIV. Am J Public Health 2001;91:400-5.
91. Wingood GM, DiClemente RJ, Mikhail I, Lang DL, McCree DH, Davies SL, Hardin JW, Hook EW 3rd, Saag M. A randomized controlled trial to reduce HIV transmission risk behaviors and sexually transmitted diseases among women living with HIV: The WiLLOW Program. J Acquir Immune Defic Syndr 2004;37 Suppl 2:S58-67.
92. Kalichman SC, Rompa D, Cage M, DiFonzo K, Simpson D, Austin J et al. Effectiveness of an intervention to reduce HIV transmission risks in HIV-positive people. Am J Prev Med 2001;21:84-92.
93. Krupitsky EM, Cheng DM, Raj A. Reduction of risky sexual behavior among hospitalized Russian substance-dependent patients: the Russian partnership to reduce the epidemic via engagement in narcology treatment (RUSSIAN PREVENT). Alcohol Clin Exp Res 2006;0:78A.
94. Rietmeijer CA. Risk reduction counselling for prevention of sexually transmitted infections: how it works and how to make it work. Sex Transm Infect 2007;83:2-9.
95. Avins AL, Lindan CP, Woods WJ, Hudes ES, Boscarino JA, Kay J et al. Changes in HIV-related behaviors among heterosexual alcoholics following addiction treatment. Drug Alcohol Depend 1997;44:47-55.
96. Collins RL, Kanouse DE, Gifford AL, Senterfitt JW, Schuster MA, McCaffrey DF et al. Changes in health-promoting behavior following diagnosis with HIV: prevalence and correlates in a national probability sample. Health Psychol 2001;20:351-60.
97. Centers for Disease Control and Prevention. The Global HIV/AIDS Pandemic, 2006. 8-11-2006. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/ mm5531a1.htm. Accessed June 26, 2007.
98. World Health Organization. Guidance on provider-initiated HIV testing and counselling in health facilities. 2007. Available at: http://www.who.int/hiv/ topics/vct/PITCguidelines.pdf. Accessed June 26, 2007.
99. Samet JH. Engaging the HIV-infected substance abuse - the classic academic approach to changing clinical practice: excruciatingly slow, extraneous, and/or effective? MedGenMed 2001;3:16.
100. Samet JH, Freedberg KA, Savetsky JB, Sullivan LM, Stein MD. Understanding delay to medical care for HIV infection: the long-term non-presenter. AIDS 2001;15:77-85.
101. Turner BJ, Cunningham WE, Duan N, Andersen RM, Shapiro MF, Bozzette SA, Nakazono T, Morton S, Crystal S, St Clair P, Stein M, Zierler S. Delayed medical care after diagnosis in a US national probability sample of persons infected with human immunodeficiency virus. Arch Intern Med 2000;160:2614-22.
102. Samet JH, Friedmann P, Saitz R. Benefits of linking primary medical care and substance abuse services: patient, provider, and societal perspectives. Arch Intern Med 2001;161:85-91.
103. Friedmann PD, Alexander JA, Jin L, D'Aunno TA. On-site primary care and mental health services in outpatient drug abuse treatment units. J Behav Health Serv Res 1999;26:80-94.
104. Friedmann PD, D'Aunno TA, Jin L, Alexander JA. Medical and psychosocial services in drug abuse treatment: do stronger linkages promote client utilization? Health Serv Res 2000;35:443-65.
105. Friedmann PD, Lemon SC, Stein MD, Etheridge RM, D'Aunno TA. Linkage to medical services in the Drug Abuse Treatment Outcome Study. Med Care 2001;39:284-95.
106. Friedmann PD, Zhang Z, Hendrickson J, Stein MD, Gerstein DR. Effect of primary medical care on addiction and medical severity in substance abuse treatment programs. J Gen Intern Med 2003;18:1-8.
107. Weisner C, Mertens J, Parthasarathy S, Moore C, Lu Y. Integrating primary medical care with addiction treatment: a randomized controlled trial. JAMA 2001;286:1715-23.
108. Rothman J, Rudnick D, Slifer M, Agins B, Heiner K, Birkhead G. Colocated substance use treatment and HIV prevention and primary care services, New York State, 1990-2002: a model for effective service delivery to a high-risk population. J Urban Health 2007;84:226-42.
109. Saitz R, Horton NJ, Larson MJ, Winter M, Samet JH. Primary medical care and reductions in addiction severity: a prospective cohort study. Addiction 2005;100:70-8.
110. Takizawa C, Cheng DM, Samet JH, Winter M, Larson MJ, Saitz R. Primary medical care can reduce HIV risk behaviors in adults with addictions. J Addict Dis. In press 2007.
111. Committee on Crossing the Quality Chasm: Adaptation to Mental Health and Addictive Disorders-Institute of Medicine. Coordinating Care for Better Mental, Substance-Use, and General Health. Improving the quality of health care for mental and substance-use conditions. Washington, DC: National Academy Press; 2006.p.210-58.
112. McLellan AT, Hagan TA, Levine M, Gould F, Meyers K, Bencivengo M, Durell J. Supplemental social services improve outcomes in public addiction treatment. Addiction 1998;93:1489-99.
113. Shwartz M, Baker G, Mulvey KP, Plough A. Improving publicly funded substance abuse treatment: the value of case management. Am J Public Health 1997;87:1659-64.
114. Kushel MB, Colfax G, Ragland K, Heineman A, Palacio H, Bangsberg DR. Case management is associated with improved antiretroviral adherence and CD4+ cell counts in homeless and marginally housed individuals with HIV infection. Clin Infect Dis 2006;43:234-42.
115. Samet JH, Rollnick S, Barnes H. Beyond CAGE. A brief clinical approach after detection of substance abuse. Arch Intern Med 1996;156:2287-93.
116. Miller WR, Rollnick S. Motivational interviewing. Preparing people to change addictive behavior. New York: The Guilford Press; 1991.
117. National Institute on Drug Abuse. Therapeutic Community. 2002. Available at: http://www.drugabuse.gov/PDF/RRTherapeutic.pdf. Accessed June 26, 2007.
118. Harrison LD, Scarpitti FR. Introduction: progress and issues in drug treatment courts. Subst Use Misuse 2002;37:1441-67.
119. Prendergast M, Podus D, Finney J, Greenwell L, Roll J. Contingency management for treatment of substance use disorders: a meta-analysis. Addiction 2006;101:1546-60.
120. Strain EC, Stitzer ML. Methadone treatment for opioid dependence. Baltimore: Johns Hopkins University Press; 1999.
121. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 1999;281:1000-5.
122. Palepu A, Tyndall MW, Joy R, Kerr T, Wood E, Press N et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend 2006;84:188-94.
123. Lucas GM, Mullen BA, Weidle PJ, Hader S, McCaul ME, Moore RD. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis 2006;42:1628-35.
124. Fiellin DA, O'Connor PG. Clinical practice. Office-based treatment of opioid-dependent patients. N Engl J Med 2002;347:817-23.
125. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000;343:1290-7.
126. Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantalon MV et al. A trial of integrated buprenorphine/naloxone and HIV clinical care. Clin Infect Dis 2006;43 Suppl 4:8184-90.
127. McCance-Katz EF, Moody DE, Smith PF, Morse GD, Friedland G, Pade P et al. Interaction between buprenorphine and antiretrovirals.II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clin Infect Dis. 2006;43:8235-8246.
128. Gourevitch MN, Friedland GH. Interactions between methadone and medications used to treat HIV infection: a review. Mt Sinai J Med 2000;67:429-36.
129. Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr 2006;41:563-72.
130. Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med 2006;144:127-34.
131. Scimeca MM, Savage SR, Portenoy R, Lowinson J. Treatment of pain in methadone-maintained patients. Mt Sinai J Med 2000;67:412-22.
132. Fogarty A, Rawstorne P, Prestage G, Crawford J, Grierson J, Kippax S. Marijuana as therapy for people living with HIV/AIDS: social and health aspects. AIDS Care 2007;19:295-301.
133. Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, Petersen KL. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007;68:515-21.